Name : Roll No. :

Invigilator's Signature :

CS/B.Pharm(OLD)/SEM-7/PT-706/2011-12 2011 PHARMACEUTICS (PHARMACEUTICAL

TECHNOLOGY)

Time Allotted : 3 Hours

Full Marks: 70

The figures in the margin indicate full marks. Candidates are required to give their answers in their own words as far as practicable.

GROUP – A

(Multiple Choice Type Questions)

1. Choose the correct alternatives for any *ten* of the following :

 $10 \times 1 = 10$

- Dissolution is affected by i)
 - a) surface area b) temperature
 - viscocity d) none of these. c)
- ii) Validation study is done by
 - Q.A. department Production department a) b)
 - Q.C. department c) d) none of these.
- The sink condition during in vitro dissolution study is iii) maintained when
 - $C_s >> C_b$ $C_s \ll C_b$ a) b) c) $C_s = C_b$ none of these. d)

7228-(O)

[Turn over



- iv) Stability testing of new drug substances & products is described in
 - a) ICH Q1B b) ICH Q1C
 - c) ICH Q6A d) ICH Q1A.
- v) Preformulation study is done is
 - a) Q.A. department b) Production department
 - c) R & D department d) Q.C. department.
- vi) Validation should be done for
 - a) four primary batches b) minimum 3 batches
 - c) minimum 2 batches d) a single batch.
- vii) Which one is the mutual prodrug?
 - a) Chloramphenicol
 - b) Chloramphenical palmitate
 - c) Benorylate
 - d) Diazepam-HCl.
- viii) The equation involved in temperature accelerated stability study is
 - a) Arrhenius b) Braggs
 - c) Noyes-Whitney d) Peppas.
- ix) Which is an example for cationic surfactant ?

2

- a) Benzalkonium chloride
- b) Polysorbate 80
- c) Sodium lauryl sulphate
- d) Sorbitol mono-oleate.

7228-(O)



a refrigerator at 15°C b)

X)

a)

- c) a place whose temperature is set at 5°C
- room temperature at 25°C. d)
- Liposomes are particles in the size range of xi)
 - 25 to 5000 nm a)
 - 10 to 10000 nm b)
 - 1 to 1000 nm c)
 - d) 20 to 15000 nm.

GROUP – B

(Short Answer Type Questions)

Answer any *three* of the following. $3 \times 5 = 15$

- 2. Give ICH guidelines the for stability testing of pharmaceuticals.
- 3. Write in brief about the process validation method for pharmaceutical operations involved in tablet production.
- 4. Discuss the effects of physical form in pre-formulation studies.
- 5. Discuss the methods of prevention of oxidative degradation.
- 6. Describe accelerated stability testing with its limitations.
- 7228-(O) 3 [Turn over

CS/B.Pharm(OLD)/SEM-7/PT-706/2011-12



Answer any three of the following. $\times 15 = 45$ What are GMP and QA ? Write down the objective of GMP.

7. Discuss the factors associated with GMP to obtain a 'zero' defect pharmaceutical product. 2 + 3 + 10

GROUP - C

- What is stability ? What are the various routes of drug 8. degradation ? Write about the physical decomposition of pharmaceutical products. Briefly discuss hydrolysis as a 2 + 2 + 5 + 6major drug degradative pathway.
- 9. Define controlled release dosage form. Describe design of controlled release or sustained release dosage form based on zero order release approximation. 4 + 11
- 10. What is 'Schedule M' under Drugs and Cosmetics Act of India, 1940 ? Write down the activities of quality assurance department. How is quality audit performed in the storage area of pharmaceutical Industry?
- 11. Describe the factors affecting the design of in vitro dissolution rate test apparatus. Describe any one dissolution apparatus in detail. Give a brief outline for the bio-availability testing protocol of a sustained release 4 + 5 + 6formulation.

7228-(O)